Speaker Profile
Ph.D., Senior Scientist, AstraZeneca
Biography
Dr. Guangai Xue specializes in ex-vivo and in-vivo CAR-T therapies, with a strong focus on upstream process development for lentiviral vectors and GMP manufacturing support. Bringing over 15 years of deep expertise in HIV-1 research, Dr. Xue offers comprehensive insight into viral vector engineering and safety design—including promoter selection, envelope optimization, and binder engineering for both ex-vivo and in-vivo platforms.
In this session, Dr. Xue will share practical insights into how vector engineering, lentiviral delivery, and manufacturing considerations collectively dictate which immune-cell populations can be successfully programmed in vivo and translated into clinical therapies. Beyond the lab, Dr. Xue actively fosters community connection as the leader of AstraZeneca’s internal tennis team, which connects over 240 members.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Razelle Kurzrock, Emory
PMWC Award Ceremony
• Antoni Ribas, UCLA Health (Luminary)
Featured Speakers
• Antoni Ribas, UCLA Health
• Gerold Meinhardt, Daiichi Sankyo
• Katy Rezvani, MD Anderson
• Javad Shahidi, BeOne
• Alicia Zhou, Cancer Research Institute
• Oren Gilad, Aprea Therapeutics
• Adam Palmer, UNC
• Trever Bivona, UCSF
• Laura Volta, Penn Medicine
• Vivek Subbiah, Stanford
• Mark Stewart, Friends of Cancer Research
Precision Immunotherapy After PD-1
Cells, bispecifics, ADCs, and new combination logic after checkpoint failure.
Biomarkers That Matter
Selecting patients for immunotherapy and targeted therapy with decision-grade biomarkers.
Resistance Biology & Adaptive Combination Strategies
How tumors adapt, and how to sequence therapy around that biology.
Which Immune Cells Can Be Programmed In Vivo?
The next wave of immune-cell engineering and where it may matter first.
Rare Cancers, Basket Trials & N-of-1 Playbooks
Moving from histology-agnostic evidence to individualized precision oncology.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
